A Highly Sensitive Biomarker of Type II Collagen C-Terminal Pro-Peptide Associated with Cartilage Formation.
C-terminal pro-peptide
ankylosing spondylitis
biomarker
cartilage
osteoarthritis
rheumatoid arthritis
type II collagen formation
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
27 Dec 2022
27 Dec 2022
Historique:
received:
08
11
2022
revised:
19
12
2022
accepted:
22
12
2022
entrez:
8
1
2023
pubmed:
9
1
2023
medline:
11
1
2023
Statut:
epublish
Résumé
The type II collagen C-terminal pro-peptide is one of the most abundant polypeptides in cartilage. The purpose of this study was to develop a competitive chemiluminescence enzyme-linked immunosorbent assay, CALC2, targeting this pro-peptide as a marker of cartilage formation. Technical assay parameters were evaluated. CALC2 level was measured after in vitro cleavage of recombinant type II collagen with bone morphogenetic protein-1 (BMP-1) and treatment of ex vivo human osteoarthritis (OA) cartilage explant model (HEX) with insulin-like growth factor-1 (IGF-1). Serum CALC2 levels were assessed in 18 patients with rheumatoid arthritis (RA), 19 patients with ankylosing spondylitis (AS), and 18 age- and sex-matched controls in cohort 1 and 8 patients with OA and 14 age- and sex-matched controls in cohort 2. Type II collagen cleavage with BMP-1 increased the CALC2 level. IGF-1 treatment increased the CALC2 levels in HEX compared with the untreated explants (p < 0.05). Results were confirmed using Western blot analysis. CALC2 levels were decreased in the patients with RA and AS compared with the healthy controls (p = 0.01 and p = 0.02, respectively). These findings indicate that CALC2 may be a novel biomarker of type II collagen formation. However, further preclinical and clinical studies are required to validate these findings.
Identifiants
pubmed: 36613894
pii: ijms24010454
doi: 10.3390/ijms24010454
pmc: PMC9820484
pii:
doi:
Substances chimiques
Collagen Type II
0
Insulin-Like Growth Factor I
67763-96-6
Peptides
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Innovation Fund Denmark and Danish Research Foundation
ID : 0153‑00086B
Références
Osteoarthritis Cartilage. 1993 Apr;1(2):121-8
pubmed: 8886088
Int J Mol Sci. 2018 Nov 06;19(11):
pubmed: 30404167
J Biol Chem. 2008 Sep 19;283(38):25879-86
pubmed: 18650436
Proc Natl Acad Sci U S A. 2013 Aug 27;110(35):14219-24
pubmed: 23940311
Osteoarthritis Cartilage. 2008 Dec;16(12):1494-500
pubmed: 18556223
J Clin Invest. 1998 Dec 15;102(12):2115-25
pubmed: 9854047
Arthritis Res Ther. 2019 Sep 3;21(1):203
pubmed: 31481084
Somatic Cell Genet. 1977 Mar;3(2):231-6
pubmed: 605383
Int J Mol Sci. 2014 Oct 17;15(10):18789-803
pubmed: 25329619
Biochem J. 1986 Aug 1;237(3):923-5
pubmed: 3800925
Sports Health. 2009 Nov;1(6):461-8
pubmed: 23015907
J Orthop Surg Res. 2018 May 29;13(1):128
pubmed: 29843748
Osteoarthr Cartil Open. 2021 Aug 14;3(4):100207
pubmed: 36474766
Arthritis Rheum. 2005 Mar;52(3):885-91
pubmed: 15751093
Bone. 2001 Sep;29(3):209-15
pubmed: 11557363
Sci Rep. 2020 Apr 7;10(1):6011
pubmed: 32265494
Clin Biochem. 2011 Apr;44(5-6):423-9
pubmed: 21223960
Osteoarthritis Cartilage. 2004 Jun;12(6):440-7
pubmed: 15135140